CD19 and B-cell chronic lymphocytic leukemia: For this purpose we have pretreated primary CD19+ B cells from healthy donor, CLL cells and Ramos B cell line with a general HDAC inhibitor trichostatin A (TSA) at 200 nM for 16 hrs and then performed Western blot analysis of total cellular level of RelB.